The rate of lung cancer in tuberculosis (TB) patients is 7 to 30% higher than that in healthy individuals. Conventional chemotherapy of lung cancer shows limited efficiency due to poor tumor tissue drug accumulation and nonspecific cytotoxicity. Epidermal growth factor receptor (EGFR) is a promising target, which is overexpressed in lung carcinomas. In the present study, EGFR-targeted nanoparticles were constructed and co-delivered cisplatin (CDDP) and doxorubicin (DOX) for lung cancer therapy. In the present research, EGF-PEG-DSPE was synthesized. Then, EGFR-targeted lipid polymeric nanoparticles (LPNs) were fabricated, which consisted of a CDDP-loaded hybrophobic polymeric core, a DOX-loaded phospholipid layer, and an outer layer of EGF-PEG-DSPE ligand. The particle size, zeta potential, stability, release behavior of LPNs were characterized. The antitumor ability of LPNs were assessed in vitro and in vivo. EGFR-targeted LPNs loaded with CDDP and DOX (EGF C/D LPNs) had a size of 141.6 nm, and could encapsulate over 80% of feed drugs. Dual drug-loaded LPNs showed synergistic effects with a combination index (CI) of 0.57. EGF C/D LPNs showed the smallest tumor volume (253 mm(3)), with a tumor inhibition ratio of 74.5%. In summary, EGF C/D LPNs were stable and released the drugs in a sustained manner. In vitro and in vivo studies revealed that EGF C/D LPNs exhibited improved anticancer activity along with lower toxicity. These results indicated the best efficiency of EGF C/D LPNs for lung carcinoma therapy.
第一作者机构：[1]Hebei Univ, Affiliated Hosp, Dept TB, 648 Dongfeng East Rd, Baoding 071000, Hebei, Peoples R China[*1]Department of Tuberculosis,Affiliated Hospital of Hebei University, 648 Dongfeng East Road,Baoding, Hebei 071000, P.R. China
通讯作者：
通讯机构：[1]Hebei Univ, Affiliated Hosp, Dept TB, 648 Dongfeng East Rd, Baoding 071000, Hebei, Peoples R China[*1]Department of Tuberculosis,Affiliated Hospital of Hebei University, 648 Dongfeng East Road,Baoding, Hebei 071000, P.R. China
推荐引用方式(GB/T 7714)：
Nan Yan.Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin[J].ONCOLOGY REPORTS.2019,42(5):2087-2096.doi:10.3892/or.2019.7323.
APA：
Nan, Yan.(2019).Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin.ONCOLOGY REPORTS,42,(5)
MLA：
Nan, Yan."Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin".ONCOLOGY REPORTS 42..5(2019):2087-2096
